CA
GTBP icon

Clearstead Advisors’s GT Biopharma GTBP Stock Holding History

Clearstead Advisors’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-865
Closed -$508 – 2954
2025
Q3 		$508 Hold
865
– – ﹤0.01% 2732
2025
Q2 		$3.1K Buy
+865
New +$2.23K ﹤0.01% 2233

Other funds holding GTBP

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CMP
Coston McIsaac & Partners Bar Harbor, Maine $443M AUM 6.68% 1-Year Est. Return
CJ
Caitlin John Brighton, Michigan $167M AUM 23.74% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Clearstead Advisors's GTBP Position: Q4 2025 in Review

Clearstead Advisors sold out of GT Biopharma (GTBP) in Q4 2025, closing a stake of 865 shares — an estimated $508 sold.

Clearstead Advisors first reported a position in GTBP in Q2 2025 and held it in 2 quarters. The position peaked at $3.1K in Q2 2025. 38 funds tracked by Wall St. Rank hold GTBP as of Q4 2025.

  • Clearstead Advisors reported no remaining GT Biopharma position as of Q4 2025 after selling out during the quarter.
  • Clearstead Advisors sold 865 GT Biopharma shares in Q4 2025, an estimated $508.
  • Clearstead Advisors first reported a position in GT Biopharma in Q2 2025 and held it in 2 quarters.
  • Clearstead Advisors's GT Biopharma position peaked at $3.1K in Q2 2025.
  • 38 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2025.

Based on Clearstead Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.